Close

Improving the lives of patients by combating metastatic cancer

We create innovative tools that provide deeper insights into cancer behaviour

The Vortex mission is to be the innovation leader in CTC capture technology that improves therapeutic decisions and saves lives

A New Window into Cancer Biology

Circulating tumour cells (CTCs) provide a real-time window into cancer biology; offering critical insights into the molecular and cellular mechanisms that drive the disease.

There is a major shift toward liquid biopsy in how cancer is studied and treated. As an innovation leader in Circulating Tumour Cell (CTC) capture technology, we’re helping researchers isolate and study circulating tumour cells — a key step in developing the next generation of anti-metastatic cancer therapies. Our advanced system offers a powerful tool to support more targeted and effective treatment development.

Circulating Tumour Cells Offer a Key Advantage

Circulating tumour cells (CTCs) provide real time insights into tumours progression. The analysis of CTCs can help to guide treatment decisions and improve patient outcomes.

Unlike circulating tumour DNA (ctDNA), CTCs are intact, viable cancer cells that provide real-time insights into tumour progression, evolution and treatment resistance. Their ability to deliver both molecular and functional information makes them invaluable for precision oncology.

VTX-1 Liquid Biopsy System

The Vortex VTX-1 Liquid Biopsy System simplifies and automates the isolation and collection of clinically relevant, viable CTCs directly from whole blood.

Liquid-biopsy-system-cartridge-design-gallery-3-2

Watch our recent webinar “Advancing Cancer Care with Liquid Biopsy”

Gain insights into the latest advancements in non-invasive cancer diagnostics. Our recent webinar explores how cutting-edge research in circulating tumour cells (CTCs) and circulating tumour
Read More
university-of-maryland-1-logo-png-transparent-small_2

Vortex and University of Maryland Baltimore Partner to Revolutionise Cancer Research

London, UK – April 2, 2025 – Vortex Biotech Holdings, a leader in oncology liquid biopsy, today announced a significant collaboration with the University of Maryland Baltimore (UMB)
Read More
s465_Nigel_Brooksby_IDAB960x640

High Profile Appointment of Nigel Brooksby as Non-Executive Chairman Of Vortex Biotech Holdings

London, UK – January 28, 2025 – Vortex Biotech Holdings, a pioneering oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as its new Non-Executi
Read More